BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
People can't get enough of this couple's Hallmark movie reviews. They don't know the painful backstory.- The most effective method to Apply Antiquated Ways of thinking in Current Brain science Practices
- Exemplary Fragrances: A Manual for Notorious Scents
- Enormous Credit And All that You Really want To Be aware
- Find the Historical backdrop of Common liberties: Advancing Equity and Equity Around the world
- Shah Capital pushes for Novavax sale, warns of proxy fight
- Top 15 Web-based Entertainment Stages for Individual Marking
- A Manual for Nations with Extraordinary Food
- Rights groups condemn Israel Police decision to ban Sudan Genocide protests nationwide
